Press release
Migraine KOL Interview
For a Detailed description and table of contents of this report please click here: https://www.reportsworldwide.com/report/biosimilar-insulin-market-access
February 08, 2017
We interviewed a neurologist based in the US who specializes in headache medicine to gauge his current and anticipated future use of acute and prophylactic agents in the treatment of episodic and chronic migraine. The drugs discussed include the anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody AMG 334 (AMGN), anti-CGRP monoclonal antibodies ALD403 (ALDR), LY2951742 (LLY) and TEV-48125 (TEVA), small molecule CGRP receptor antagonists atogepant (AGN), ubrogepant (AGN) and telcagepant (MRK), small molecule 5HT1F receptor agonist lasmiditan (CLCD), Botox (AGN), triptans Imitrex (GSK), Maxalt (MRK) and Topamax (JNJ), Treximet (PTX), Atacand (AZN) and TI-001.
To Get Sample Copy of Report please visit @ https://www.reportsworldwide.com/enquiry?report_id=41334
About ReportsWorldwide.com
ReportsWorldwide.com is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, ReportsWorldwide.com offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.
Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
US
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine KOL Interview here
News-ID: 658653 • Views: …
More Releases from ReportsWorldwide
World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence…
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports.
Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors.
Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that…
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA
ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports.
This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers:
• CommScope/Airvana
• Comba Telecom
• Ericsson
• Huawei Technologies
• Nokia
• SpiderCloud
• ZTE Corporation
This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021.
To view a detailed description and Table of…
More Releases for CGRP
CGRP Inhibitor Market Sees Major Uptake Across Hospitals Pharmacies and Specialt …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " CGRP Inhibitor Market- (By Treatment (Preventive, Acute), By Route of Administration (Oral, Nasal, Intravenous), By End-User (Hospitals, Pharmacies, Specialty Clinics)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the CGRP Inhibitor Market is valued at USD 3.3 Bn in 2024, and it is expected to reach USD…
Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Outlook 2025-203 …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Size and Projected Growth Rate?
The market for inhibitors of the calcitonin gene-related peptide (CGRP) has seen quick expansion in recent years. Its size is projected to increase from $2.87 billion in 2024 to $3.17 billion in 2025, reflecting a compound annual growth rate (CAGR)…
CGRP Inhibitors Market Forecasted to Expand Rapidly Through 2032 - Persistence M …
The global CGRP inhibitors market has emerged as a significant segment within the pharmaceutical landscape, primarily focused on the treatment and prevention of migraines-a neurological disorder affecting millions worldwide. CGRP (Calcitonin Gene-Related Peptide) inhibitors are a novel class of drugs designed to target the CGRP neuropeptide or its receptor, which play a critical role in migraine pathophysiology. By modulating the activity of CGRP, these inhibitors effectively reduce the frequency, intensity,…
CGRP Inhibitor Market for Migraine Prevention and Acute Relief Across Multiple D …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " CGRP Inhibitor Market- (By Treatment (Preventive, Acute), By Route of Administration (Oral, Nasal, Intravenous), By End-User (Hospitals, Pharmacies, Specialty Clinics)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the CGRP Inhibitor Market is valued at USD 3.3 Bn in 2024, and it is expected to reach USD…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
CGRP Antagonists market size increases with a CAGR of 19.1% during 2023-2029
The global CGRP Antagonists market size was valued at USD 2935.6 million in 2022 and is forecast to a readjusted size of USD 10000 million by 2029 with a CAGR of 19.1% during review period. The global CGRP antagonists market is poised for significant growth in the upcoming years, driven by a surge in demand for migraine treatments and advancements in biotechnology. As healthcare researchers delve deeper into the mechanisms…
